Adaptimmune Therapeutics plc (ADAP) is priced at $5.89 after the most recent trading session. At the very opening of the session, the stock price was $6.2984 and reached a high price of $6.3118, prior to closing the session it reached the value of $6.23. The stock touched a low price of $5.79.
Recently in News on November 20, 2020, Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day. – SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Adaptimmune Therapeutics plc had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $6.41 on 01/11/21, with the lowest value was $5.25 for the same time period, recorded on 01/04/21.
Adaptimmune Therapeutics plc (ADAP) full year performance was 47.62%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Adaptimmune Therapeutics plc shares are logging -56.04% during the 52-week period from high price, and 194.50% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.00 and $13.40.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1660600 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Adaptimmune Therapeutics plc (ADAP) recorded performance in the market was 9.28%, having the revenues showcasing -29.55% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 882.15M, as it employees total of 400 workers.
Market experts do have their say about Adaptimmune Therapeutics plc (ADAP)
During the last month, 3 analysts gave the Adaptimmune Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 6.38, with a change in the price was noted -3.10. In a similar fashion, Adaptimmune Therapeutics plc posted a movement of -34.48% for the period of last 100 days, recording 1,433,677 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADAP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Adaptimmune Therapeutics plc (ADAP)
Raw Stochastic average of Adaptimmune Therapeutics plc in the period of last 50 days is set at 80.00%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 78.70%. In the last 20 days, the company’s Stochastic %K was 89.02% and its Stochastic %D was recorded 91.03%.
Bearing in mind the latest performance of Adaptimmune Therapeutics plc, several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 9.28%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -30.71%, alongside a boost of 47.62% for the period of the last 12 months. The shares increased approximately by 2.08% in the 7-day charts and went down by 45.43% in the period of the last 30 days. Common stock shares were lifted by -29.55% during last recorded quarter.